Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion

A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the <i>*3</i> mutation lack CYP3A5 activity, which results in...

Full description

Saved in:
Bibliographic Details
Main Authors: Naoki Yoshikawa (Author), Hidemi Takeshima (Author), Masaaki Sekine (Author), Keiichi Akizuki (Author), Tomonori Hidaka (Author), Kazuya Shimoda (Author), Ryuji Ikeda (Author)
Format: Book
Published: MDPI AG, 2021-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4b9c0b28b4d740e2a00457c7f43a5a23
042 |a dc 
100 1 0 |a Naoki Yoshikawa  |e author 
700 1 0 |a Hidemi Takeshima  |e author 
700 1 0 |a Masaaki Sekine  |e author 
700 1 0 |a Keiichi Akizuki  |e author 
700 1 0 |a Tomonori Hidaka  |e author 
700 1 0 |a Kazuya Shimoda  |e author 
700 1 0 |a Ryuji Ikeda  |e author 
245 0 0 |a Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion 
260 |b MDPI AG,   |c 2021-04-01T00:00:00Z. 
500 |a 10.3390/ph14040353 
500 |a 1424-8247 
520 |a A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the <i>*3</i> mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and <i>CYP3A5</i> polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the <i>*1/*3</i> and <i>*3/*3</i> groups based on <i>CYP3A5</i> polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the <i>*1/*3</i> and <i>*3/*3</i> groups in the time course of the C/D ratio during this period (<i>p</i> < 0.05). This study reveals the effects of <i>CYP3A5</i> polymorphism on continuous changes in tacrolimus blood concentration. 
546 |a EN 
690 |a cytochrome P450 family 3 subfamily a member 5 
690 |a tacrolimus 
690 |a gene polymorphism 
690 |a therapeutic drug monitoring 
690 |a hematopoietic stem cell transplantation 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 14, Iss 4, p 353 (2021) 
787 0 |n https://www.mdpi.com/1424-8247/14/4/353 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/4b9c0b28b4d740e2a00457c7f43a5a23  |z Connect to this object online.